<DOC>
	<DOCNO>NCT00126412</DOCNO>
	<brief_summary>The study design study effectiveness 123I-mIBG diagnostic imaging agent evaluate patient know suspected neuroblastoma phaeochromocytoma .</brief_summary>
	<brief_title>Meta-Iodobenzylguanidine ( 123I mIBG ) Scintigraphy Patients Being Evaluated Phaeochromocytoma Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Subject must either : 1. know suspected neuroblastoma OR 2. know suspected phaeochromocytoma Subjects eligible study clinically active , serious , lifethreatening disease neuroblastoma phaeochromocytoma life expectancy le 30 day participation study might compromise management subject reason judgement investigator ( ) make subject unsuitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Phaeochromocytoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>diagnosis</keyword>
	<keyword>123I-mIBG</keyword>
</DOC>